Abstract: Objection The purpose of this study was to investigate the efficacy of tripterygium glycosides combined with magnesium isoglycyrrhizinate in treatment of patients with autoimmune hepatitis（AIH）. Methods 70 patients with AIH were recruited in our hospital between June 2016 and February 2018,and were randomly divided into combined and control group,with 35 cases in each group. On the basis of routine prednisolone treatment,the patients in the control group were treated with magnesium isoglycyrrhizinate,and those in the combined group were treated with tripterygium glycyrrhizinate and magnesium isoglycyrrhizinate for six months. Methods At the end of six month treatment,serum ALT,AST and alkaline phosphatase levels in the combination treatment group were （52.6±7.3） U/L,（45.3±7.8） U/L and （68.3±2.8） U/L,significantly lower than [（78.4±10.1） U/L,（77.2±8.9） U/L and （90.5±4.6） U/L,P<0.05） in the control group;plasma immunoglobulin （IgG）,IgA,IgM and globulin levels in the combined group were （11.3±2.5） mg/mL,（2170.3±101.7） mg/mL,（2218.3±97.2） mg/mL and （14.6±3.9） g/L,significantly lower than（14.8±2.8） mg/mL,（2857.2±108.9） mg/mL,（2919.4±113.6） mg/mL and （18.9±3.8） g/L,respectively,P<0.05] in the control;serum hyaluronic acid,laminin and type III procollagen levels in the combination group were （112.5±6.7） g/L,（60.7±4.8） g/L and （52.3±3.5） g/L,which were statistically significantly lower than [（164.9±7.4） g/L,（82.8±5.6） g/L and （79.6±4.7） g/L,P<0.05] in the control group. Conclusion The application of tripterygium glycosides and magnesium isoglycyrrhizinate might effectively improve liver function tests,inhibit immune response and lighten the degree of liver fibrosis in patients with AIH.

Key words: Autoimmune hepatitis, Tripterygium glycosides, Magnesium isoglycyrrhizinate, Immunoglobulin, Therapy